Protagenic TherapeuticsPTIX
13F holders, Q4 2024 (December 31)9holders −2
0new positions
2sold out
$0.50avg. 13F price*
At the end of Q4 2024, 9 institutions reported holding Protagenic Therapeutics Inc. (PTIX) in their 13F filings, down 2 from Q3 2024. 0 opened new positions and 2 sold out. The largest holders were Geode Capital Management, LLC ($22K), Vanguard Group Inc. ($17K) and Osaic Holdings, Inc. ($10K).
- Company
- Protagenic Therapeutics Inc.
- CUSIP
- 74365N202
- Latest filing quarter
- Q1 2025
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 2 | $26K |
All 13F filers, Q3 2024 → Q4 2024: 26,657 shares bought and 41,830 shares sold, net −15,173 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 9 holders
| Geode Capital Management, LLC | 0.00% | Add +66.1% | 43,280 | $22K |
| Vanguard Group Inc. | 0.00% | No change | 33,166 | $17K |
| Osaic Holdings, Inc. | 0.00% | No change | 21,414 | $10K |
| Virtu Financial LLC | 0.00% | Add +36.2% | 17,866 | $9K |
| UBS Group AG | 0.00% | Add +48.0% | 14,414 | $7K |
| State Street Corp. | 0.00% | No change | 13,812 | $7K |
| Tower Research Capital LLC (TRC) | 0.00% | Reduce -13.5% | 5,909 | $3K |
| Bank of America Corp. | 0.00% | Add +21.9% | 50 | $24 |
| Cwm, LLC | 0.00% | No change | 1 | $0 |
"% of holder's portfolio" is PTIX's weight in each manager's 13F, not the share of Protagenic Therapeutics Inc. the manager owns.